The Anti-Cancer Drugs Market will Generate $122.3Bn in 2018, a new study predicts, According to a New Study on ASDReports

Tuesday 30 September 2014, Amsterdam

A new report, now available on ASDReports, forecasts the world cancer treating drugs market will achieve revenues of $122.3 billion in 2018. That revenue prediction and others appear in Anti-Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2014-2024, published in August 2014.

That analysis predicts the global cancer-treating drugs market will continue to expand over the forecasted period, 2014 to 2024, although growth will slow towards the end of that period. The sales expansion will be driven by an increase in the number of cases of cancer, due to the rise in life expectancy, leading to an ageing population worldwide.

Katie Noon, a pharmaceutical industry analyst, said: “The anti-cancer drugs market will continue to grow at a steady pace over the next ten years, and the development of new therapy options will continue to drive sales. Advances in technology, including diagnostics and delivery methods, will advance the anti-cancer drugs industry.

“Cancer treatment is becoming more personalised, with research and development (R&D) focused on targeted and immunotherapies, especially monoclonal antibodies (mAbs). We believe the use of drugs in combination will yield progress and raise sales. The industry will be affected by some drugs losing patent protection, and generic drugs entering the market. This will challenge the sales of existing blockbuster drugs, and may cause some therapy areas to become crowded. One challenge will be whether a drug is seen as cost-effective, as healthcare providers make savings owing to uncertain economies.”

The new study shows revenue forecasts to 2024 at world market, submarket, product and national level. It forecasts sales of these world-level submarkets:

•     Immunotherapy
•     Chemotherapies
•     Targeted treatments
•     Hormone-based agents.

That investigation also predicts revenues to 2024 for 25 leading products, including Herceptin, Avastin and Gleevec/Glivec. It also forecasts sales of 23 emerging and rising drugs. Research, data and analyses cover activities of Roche, Novartis, Celgene, Eli Lilly, AstraZeneca and other companies. The analysis shows 128 tables, 145 charts and four interviews with authorities in that field.

That work also discusses R&D and commercial news, and predicts revenues to 2024 for leading regional and national markets. The work analyses the United States (US), Japan, the EU5 countries – Germany, France, the UK, Spain and Italy – and the BRIC group – Brazil, Russia, India and China.

Anti-Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2014-2024 adds to the reports on industries and markets in healthcare. Those studies analyse medical devices, diagnostics and pharmaceuticals.